Join the Oncology Voice Network. Join for Free
COMP: How HR Determines Compensation and Titles for Job Offers
MSL job negotiation HR compensation strategies job offer negotiation tips internal equity in job offers sign-on bonuses in employment

COMP: How HR Determines Compensation and Titles for Job Offers


Share This Article


Summary

In this episode, Chris Castin joins Tom Caravela to delve into the intricacies of compensation and negotiation processes for MSL roles. They explore how to prepare for job offer negotiations while emphasizing the importance of transparency and the risks of over-negotiating. Chris provides insights into HR perspectives and how offers are determined using formulas and data, highlighting the significance of internal equity. The discussion covers the role of job titles, leveling, and the impact of experience on role effectiveness. They also analyze written job offers, discuss sign-on bonuses, and offer advice on responding to offers with effective negotiation strategies. The episode concludes with practical advice for MSLs navigating job offers.

My guest today is Chris Castin, Senior Director, Talent Acquisition NKARTA Therapeutics and we discuss how HR departments determine compensation and titles for job offers

Chris shares…

👉 The HR formula for determining job offers
👉 What you need to know to negotiate an offer
👉 What information is expected in advance of the job offer
👉 How and why sign-on bonuses are used
👉 The way HR determines titles and leveling

Click for Source
MSL job negotiation, HR compensation strategies, job offer negotiation tips, internal equity in job offers, sign-on bonuses in employment

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Negotiate a Job Offer
Partner Avatar MSL Talk: Tom Caravela

How to Negotiate a Job Offer

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN